ライフサイエンスコーパス: cell-free DNA

1 oplets to represent circulating viral DNA or cell-free DNA.

2 or each case and detected by qPCR within the cell-free DNA.

3 nology was also used to remove contaminating cell-free DNA.

4 crobial samples and removal of contaminating cell-free DNA.

5 t DNA extracted from plasma reflected fungal cell-free DNA.

6 es by parallel sequencing of maternal plasma cell-free DNA, 3 aberrant genome representation (GR) pro

7 for cell growth inhibition and -log AE (AE = cell-free DNA alkylation efficiency) were observed, with

8 Both release of cell-free DNA and apoptosis could be significantly reduc

9 n knowledge of the methylomes of circulating cell-free DNA and its cellular contributors.

10 NA-elastase and histone-elastase complexes), cell-free DNA, and neutrophil biomarkers were quantified

11 mparing placenta to non-pregnant circulating cell-free DNA are recapitulated in pregnant circulating

12 Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequen

13 2AX activation was in the same rank order as cell-free DNA break induction, although the amount of br

14 , which exploits the diagnostic potential of cell-free DNA by determining not only the presence but a

15 Our results demonstrate that cell-free DNA can be used to detect an organ-specific si

16 However, circulating cell-free DNA carrying tumor-specific alterations (circu

17 ssociated copy number variation (CNV) in the cell free DNA (cfDNA) fraction of patient blood plasma.

18 Cell free DNA (cfDNA) has received increasing attention

19 atic disease, deep sequencing of circulating cell free DNA (cfDNA) obtained from patient's blood yiel

20 ively parallel sequencing of maternal plasma cell-free DNA (cfDNA testing) accurately detects fetal a

21 on status between tumor-specific circulating cell-free DNA (cfDNA) and tumor tissue, and the evaluati

22 sis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and

23 Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profili

24 er 16, 2014, to August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples from

25 Detection of amplification in cell-free DNA (cfDNA) from blood is strongly associated

26 patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimall

27 ng for aneuploidy by analysis of circulating cell-free DNA (cfDNA) have shown high sensitivity and sp

28 Quantification of cell-free DNA (cfDNA) in circulating blood derived from

29 lung transplant recipients by sequencing of cell-free DNA (cfDNA) in plasma.

30 However, low quantities of cell-free DNA (cfDNA) in the blood and sequencing artifa

31 Circulating cell-free DNA (cfDNA) is emerging as a powerful monitori

32 Cell-free DNA (cfDNA) is shed into the blood by tumor ce

33 e of Kaposi sarcoma herpesvirus sequences in cell-free DNA (cfDNA) isolated from the blood of patient

34 een circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive ra

35 arrangements would not have been detected by cell-free DNA (cfDNA) screening.

36 Cell-free DNA (cfDNA) testing for fetal trisomy is highl

37 e found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in H

38 Cell-free DNA (cfDNA) was isolated from 6 AH samples fro

39 Cellular and cell-free DNA (cfDNA) were isolated from each lavage.

40 ion, immature granulocyte (IG) count, plasma cell-free DNA (cfDNA), and plasma citrullinated histone

41 A tumor-derived fraction of circulating cell-free DNA (cfDNA), isolated from blood samples, cont

42 By deep sequencing cell-free DNA (cfDNA), isolated from circulating blood p

43 Cell-free DNA circulating in serum is a candidate molecu

44 We analyzed cell-free DNA circulating in the blood of heart transpla

45 irculating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clini

46 NA are recapitulated in pregnant circulating cell-free DNA, confirming the ability to detect differen

47 The copy number of donor-derived cell-free DNA (dd-cfDNA) in blood correlates with acute

48 Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allogr

49 of a variety of human genetic diseases using cell-free DNA extracted from maternal plasma samples in

50 s in the context of prenatal diagnosis using cell free DNA for monogenic diseases that segregate in a

51 Because cell-free DNA from brain and spinal cord tumors cannot u

52 We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained th

53 ive diagnosis of fetal genetic disease using cell-free DNA from maternal plasma samples obtained in t

54 t of unmatched samples including circulating cell-free DNA from non-pregnant and pregnant female dono

55 Here, analysis of tumor samples and cell-free DNA from patients with advanced prostate cance

56 ingle-stranded DNA sequencing (ssDNA-seq) of cell-free DNA from plasma and other bodily fluids is a p

57 gh massive shotgun sequencing of circulating cell-free DNA from the blood, we identified hundreds of

58 d observed significantly increased levels of cell-free DNA from the donor genome at times when an end

59 Plasma genotyping of cell-free DNA has the potential to allow for rapid nonin

60 placental apoptosis/necrosis and release of cell-free DNA, hence confirming that maternal serum/plas

61 thylation and fragment length in circulating cell-free DNA, identify differentially methylated region

62 ns and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA me

63 Detection of cell-free DNA in liquid biopsies offers great potential

64 non-invasive methods of fetal testing using cell-free DNA in maternal plasma.

65 We used sequencing of cell-free DNA in plasma to investigate drug-virome inter

66 atic tissues of mice and increased levels of cell-free DNA in plasma.

67 Cell-free DNA in serum or plasma is emerging as a useful

68 This testing utilizes cell-free DNA in the maternal circulation to predict fet

69 The concentration of beta-globin cell-free DNA in the supernatant, measured using real-ti

70 Circulating cell-free DNA is primarily derived from hematopoietic ce

71 of CEPs (P < 0.05) and led to a decrease in cell-free DNA levels (P < 0.05).

72 t MDS genome would be a major contributor to cell-free DNA levels in MDS patients as a result of inef

73 othelial precursors (CEP) and tumor-specific cell-free DNA levels were assessed.

74 ructural motifs which relies on splint-free, cell-free DNA ligations and recycling of side-products b

75 hat maternal serum/plasma concen-trations of cell-free DNA may act as a biomarker of trophoblast well

76 d to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival ou

77 tect differential methylation in circulating cell-free DNA mixtures.

78 te that TP53 mutations appear in circulating cell-free DNA obtained from patients with de-differentia

79 tissue-of-origin mapping in the circulating cell-free DNA of 59 patients with lung or colorectal can

80 The study revealed that cell-free DNA of HHV-6 was detected more frequently in b

81 e (ccf) fetal DNA comprises 3-20% of all the cell-free DNA present in maternal plasma.

82 Fetal cells and cell-free DNA reach the maternal circulation during norm

83 A replication by geminin that is observed in cell-free DNA replication extracts is reversed by the ad

84 We exploit an improved mammalian cell-free DNA replication system to analyse quiescence a

85 In a cell-free DNA replication system, extracts from BLM-trea

86 n of cellular DNA replication in a mammalian cell-free DNA replication system.

87 binding domain of ORC1 are unable to support cell-free DNA replication.

88 mes of placenta and non-pregnant circulating cell-free DNA reveal many of the 51,259 identified diffe

89 es in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a sol

90 ic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven

91 2878) and genomic data from paired tumor and cell-free DNA samples revealing loss of heterozygosity.

92 e low proportion of tumor-derived DNA in the cell-free DNA scenarios.

93 ptomatic pregnant women who underwent plasma cell-free DNA sequencing for clinical prenatal aneuploid

94 We show that maternal plasma cell-free DNA sequencing for noninvasive prenatal testin

95 Cell-free DNA shed by cancer cells has been shown to be

96 rimary brain tumor in adults, examination of cell-free DNA uncovered patterns of tumor evolution, inc

97 Cell-free DNA was isolated from 122 of 125 plasma sample

98 Cell-free DNA was isolated from the AH, and sequencing l

99 Cell-free DNA was quantified in plasma samples.

100 We directly sequenced cell-free DNA with high-throughput shotgun sequencing te